Spheroid Culture of Mesenchymal Stromal Cells Results in Morphorheological Properties Appropriate for Improved Microcirculation.
cell mechanics
mesenchymal stromal cells
mesenspheres
microcirculation mimetics
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
17 Apr 2019
17 Apr 2019
Historique:
received:
21
11
2018
revised:
21
01
2019
entrez:
25
4
2019
pubmed:
25
4
2019
medline:
25
4
2019
Statut:
epublish
Résumé
Human bone marrow mesenchymal stromal cells (MSCs) are used in clinical trials for the treatment of systemic inflammatory diseases due to their regenerative and immunomodulatory properties. However, intravenous administration of MSCs is hampered by cell trapping within the pulmonary capillary networks. Here, it is hypothesized that traditional 2D plastic-adherent cell expansion fails to result in appropriate morphorheological properties required for successful cell circulation. To address this issue, a method to culture MSCs in nonadherent 3D spheroids (mesenspheres) is adapted. The biological properties of mesensphere-cultured MSCs remain identical to conventional 2D cultures. However, morphorheological analyses reveal a smaller size and lower stiffness of mesensphere-derived MSCs compared to plastic-adherent MSCs, measured using real-time deformability cytometry and atomic force microscopy. These properties result in an increased ability to pass through microconstrictions in an ex vivo microcirculation assay. This ability is confirmed in vivo by comparison of cell accumulation in various organ capillary networks after intravenous injection of both types of MSCs in mouse. The findings generally identify cellular morphorheological properties as attractive targets for improving microcirculation and specifically suggest mesensphere culture as a promising approach for optimized MSC-based therapies.
Identifiants
pubmed: 31016116
doi: 10.1002/advs.201802104
pii: ADVS1021
pmc: PMC6469243
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1802104Subventions
Organisme : European Research Council
ID : 282060
Pays : International
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
Oliver Otto is cofounder and shareholder of Zellmechanik Dresden GmbH, a company selling real‐time deformability cytometry devices. The authors affirm that there are no other conflicts of interest (either financial or personal).
Références
Transplantation. 1968 Mar;6(2):230-47
pubmed: 5654088
Catheter Cardiovasc Interv. 2005 Jul;65(3):321-9
pubmed: 15954106
Stem Cells. 2004;22(3):377-84
pubmed: 15153614
Blood. 2003 May 1;101(9):3722-9
pubmed: 12506037
Stem Cells Dev. 2010 May;19(5):607-14
pubmed: 19824807
Haematologica. 2009 Aug;94(8):1151-6
pubmed: 19546436
Gene Expr. 2007;13(4-5):217-26
pubmed: 17605296
Mol Ther. 2012 Jul;20(7):1424-33
pubmed: 22453767
Clin Oral Implants Res. 2010 Feb;21(2):174-81
pubmed: 19709059
Blood. 2009 Apr 30;113(18):4197-205
pubmed: 19036701
Annu Rev Biophys. 2017 May 22;46:337-356
pubmed: 28532214
Transplant Proc. 2007 Mar;39(2):573-6
pubmed: 17362785
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17588-93
pubmed: 25422455
J Mech Behav Biomed Mater. 2012 Jul;11:63-71
pubmed: 22658155
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Nat Mater. 2010 Jan;9(1):82-8
pubmed: 19838182
Sci Adv. 2017 Jun 14;3(6):e1602536
pubmed: 28630905
Tissue Eng. 2002 Dec;8(6):901-10
pubmed: 12542936
Stem Cells Dev. 2015 Jan 15;24(2):253-63
pubmed: 25162829
Bone. 1992;13(1):81-8
pubmed: 1581112
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13724-9
pubmed: 20643923
Exp Hematol. 1976 Sep;4(5):267-74
pubmed: 976387
Nature. 2010 Aug 12;466(7308):829-34
pubmed: 20703299
J Cell Physiol. 1998 Jul;176(1):57-66
pubmed: 9618145
Blood. 2002 May 15;99(10):3838-43
pubmed: 11986244
Biophys J. 2010 Oct 20;99(8):2479-87
pubmed: 20959088
Blood. 2008 Feb 1;111(3):1327-33
pubmed: 17951526
Sci Rep. 2017 May 31;7(1):2549
pubmed: 28566689
Cytotherapy. 2003;5(1):7-18
pubmed: 12745583
Exp Hematol. 2012 Nov;40(11):934-44
pubmed: 22863570
Stem Cells Dev. 2012 Apr 10;21(6):937-47
pubmed: 21689066
Liver Int. 2014 Jan;34(1):33-41
pubmed: 23782511
Blood. 2001 Mar 1;97(5):1227-31
pubmed: 11222364
Stem Cells. 2016 Feb;34(2):357-66
pubmed: 26418955
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Nat Methods. 2015 Mar;12(3):199-202, 4 p following 202
pubmed: 25643151
Blood. 2006 Jan 1;107(1):367-72
pubmed: 16141348
J Exp Med. 2013 Jul 1;210(7):1351-67
pubmed: 23776077
Eur Heart J. 2007 Mar;28(6):766-72
pubmed: 17298974
Thorax. 2014 Jul;69(7):623-9
pubmed: 24706039
J Biol Chem. 2008 May 9;283(19):13100-7
pubmed: 18334485
Cell Tissue Res. 2012 Mar;347(3):701-11
pubmed: 21833761
Biophys J. 2015 Apr 21;108(8):1856-69
pubmed: 25902426
Cell. 2007 Oct 19;131(2):324-36
pubmed: 17956733
Nature. 2010 Jan 28;463(7280):485-92
pubmed: 20110992
ACS Biomater Sci Eng. 2017 Nov 13;3(11):2962-2973
pubmed: 33418716
Exp Hematol. 2000 Jun;28(6):707-15
pubmed: 10880757
Tissue Eng Part A. 2015 May;21(9-10):1705-19
pubmed: 25661745
Biophys J. 2015 Nov 17;109(10):2023-36
pubmed: 26588562
Adv Sci (Weinh). 2019 Feb 19;6(8):1802104
pubmed: 31016116
Stem Cells. 2012 Jul;30(7):1455-64
pubmed: 22495904
Blood. 2004 Jun 15;103(12):4619-21
pubmed: 15001472
Front Immunol. 2012 Sep 26;3:297
pubmed: 23056000
Bone Marrow Transplant. 2009 Feb;43(3):245-51
pubmed: 18820709
Transplantation. 1974 Apr;17(4):331-40
pubmed: 4150881
PLoS One. 2012;7(9):e45237
pubmed: 23028868
Dis Colon Rectum. 2005 Jul;48(7):1416-23
pubmed: 15933795
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15696-701
pubmed: 19717452